Julian Adams, Gamida Cell CEO
April 26, 2022 10:40 AM EDTUpdated 12:06 PM
R&D

Gami­da Cell gets IND cleared and clin­i­cal hold lift­ed, paving the way for PhI/II clin­i­cal tri­als

Paul Schloesser

Associate Editor

The small Boston-based cell ther­a­py out­fit Gami­da Cell re­cent­ly axed 10% of its work­force in or­der to slow the burn rate. But now it’s got …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times